Prime Medicine Files 8-K

Ticker: PRME · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1894562

Prime Medicine, Inc. 8-K Filing Summary
FieldDetail
CompanyPrime Medicine, Inc. (PRME)
Form Type8-K
Filed DateSep 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: filing, disclosure, financials

TL;DR

Prime Medicine dropped an 8-K, check it for Reg FD and financials.

AI Summary

Prime Medicine, Inc. filed an 8-K on September 8, 2025, to report on matters including Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware with its principal executive offices in Cambridge, MA, operates in the Biological Products sector.

Why It Matters

This filing provides important updates and disclosures from Prime Medicine, Inc. to the public and investors.

Risk Assessment

Risk Level: low — This is a routine filing and does not indicate any immediate financial distress or significant operational changes.

Key Players & Entities

  • Prime Medicine, Inc. (company) — Registrant
  • September 8, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • Cambridge, MA (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Prime Medicine, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on September 8, 2025.

In which state is Prime Medicine, Inc. incorporated?

Prime Medicine, Inc. is incorporated in Delaware.

What is the business address of Prime Medicine, Inc.?

The business address of Prime Medicine, Inc. is 60 First Street, Cambridge, MA 02141.

What is the Standard Industrial Classification (SIC) code for Prime Medicine, Inc.?

The SIC code for Prime Medicine, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-08 08:04:35

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 8, 2025, Prime Medicine, Inc. (the "Company") posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company's website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation, dated September 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 8, 2025 Prime Medicine, Inc. By: /s/ Allan Reine Name: Allan Reine, M.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.